|
|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2026
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/34373
| Title: | THE GUT MICROBIOME AS A DETERMINANT OF CANCER DEVELOPMENT AND RESPONSE TO IMMUNOTHERAPY |
| Authors: | Mamonov, Vladislav |
| Keywords: | gut microbiome;dysbiosis;immunotherapy;carcinogenesis;microbiota modulation |
| Issue Date: | 2026 |
| Publisher: | Centrul Editorial-Poligrafic Medicina |
| Citation: | Mamonov, Vladislav. THE GUT MICROBIOME AS A DETERMINANT OF CANCER DEVELOPMENT AND RESPONSE TO IMMUNOTHERAPY. In: MedEspera 2026, p. 558. ISBN 978-9975-82-486-6. |
| Abstract: | Introduction. The gut microbiome has emerged as a key regulator of host metabolism, immune homeostasis, and inflammatory pathways. Increasing evidence indicates that alterations in gut microbial composition, commonly referred to as dysbiosis, may contribute to tumor initiation and progression. In addition to its role in carcinogenesis, the gut microbiome has been recognized as an important determinant of variability in patient response to oncological therapies, particularly immune checkpoint inhibitors. Aim of study. This study aimed to synthesize recent evidence regarding the role of the gut microbiome in cancer development and to evaluate its potential impact on therapeutic response, with a particular focus on immunotherapy. Methods and materials. A narrative review of scientific literature published between 2020 and 2025 was conducted using major biomedical databases. Clinical and experimental studies investigating host -microbiome interactions in cancer were analyzed. Particular attention was given to molecular mechanisms linking microbiota alterations to carcinogenesis, as well as to therapeutic approaches targeting microbiome modulation, including fecal microbiota transplantation, probiotics, and immune checkpoint inhibitor therapy. Results. Accumulating evidence demonstrates significant differences in microbial diversity and composition between healthy individuals and patients with cancer. Dysbiosis has been associated with increased intestinal permeability, systemic inflammation, and immune dysregulation, factors that may facilitate tumor development. Several microbial species have been implicated in tumorigenesis; notably, increased abundance of Fusobacterium nucleatum has been consistently reported in colorectal cancer and associated with unfavorable prognosis and increased recurrence risk. Conversely, depletion of butyrate-producing bacteria, such as Faecalibacterium prausnitzii, may promote pro-inflammatory signaling and tumor progression. Importantly, multiple studies indicate that patients with higher gut microbial diversity exhibit significantly improved responses to immune checkpoint inhibitors targeting PD-1/PD-L1 pathways. Emerging data further suggest that fecal microbiota transplantation may restore responsiveness to immunotherapy in selected non-responder patients. Conclusions. The gut microbiome represents a critical interface between environmental factors, host immunity, and cancer biology. Modulation of the intestinal microbiota may become an important strategy for improving therapeutic outcomes and enabling personalized oncological treatment. |
| metadata.dc.relation.ispartof: | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 |
| URI: | https://medespera.md/documents/abstract-book-4.pdf https://repository.usmf.md/handle/20.500.12710/34373 |
| ISBN: | 978-9975-82-486-6 |
| Appears in Collections: | MedEspera 2026
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|